Sep 21, 2018
Pharmaceutical Executive
A look at the Drug SUpply Chain Security Act and how it impacts serialization and third-party logistics licensing.
Sep 20, 2018
FDA is joining with other federal health agencies and the biomedical research community to advance the science, regulatory policies and reimbursement strategies to support innovative new medicines to combat infectious diseases.
Sep 18, 2018
Pharmaceutical Executive
Small biotech companies benefit more from partnering with CROs rather than hiring a chief medical officer.
Sep 17, 2018
For pharma leaders, AI can bring about a new reality of seeing a multitude of possible paths, forecasting the interplay of multi-dimensional trends, and charting patient journeys that are based on reality, writes Aswin Chandrakantan.
Sep 11, 2018
Pharmaceutical Executive
In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.
Sep 10, 2018
With the rise in industry programs for developing biosimilars, tensions are high as innovator firms back strategies that appear designed to delay competition. Jill Wechsler reports.
Sep 04, 2018
Pharmaceutical Executive
To help combat the nation’s opioid epidemic, FDA is promoting a more tailored approach to developing and testing effective analgesics, with the aim of bringing less addictive pain treatments to market more quickly.
Aug 24, 2018
A recently announced collaboration between EUnetHTA, WHO, and ISPOR brings home the fact that there is still no real agreement on a definition of HTA, writes Reflector.
Aug 23, 2018
Just as biopharma companies are mastering the complexities of the five-year-old federal Open Payments program, state governments are enacting a host of additional marketing and disclosure rules and restrictions on industry interactions with HCPs.
Aug 21, 2018
Pharmaceutical Executive
A list of three key elements when looking at public-private partnerships to tackle public health challenges.
lorem ipsum